# Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

> **NCT03039114** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 26 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Parsaclisib
- **DRUG:** Hexal
- **DRUG:** Gazyvaro

## Key facts

- **NCT ID:** NCT03039114
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-15
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03039114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03039114, "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03039114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*